CTIX Alerts 08/25/2014 17:28:19 $CTIX Interesting post. I

New Post Public Reply Private Reply Replies (0) Message Board
Jake13
CTIX Alerts 08/25/2014 17:28:19 $CTIX
Interesting post. I try and let you (and a few others) do the heavy lifting for me on potential valuations for CTIX. My mind turns to mush when I start contemplating all the potential inputs and thru puts and end points. Mush.

About K: Can't get around K being unrewarded partially because it has been so successful in trials. Keeps proving to be very safe, no end to cohorts in sight. But, I know what all this really adds up to in the end, MORE $$$$.

While B and P likely will find faster routes to market, I still believe the most valuable gem to be K.

Can't forget about the autism compound and other goodies in the vault either.

BigK, thanks again for a very enlightening post.


I think so BK. You add so much to this board, its time for the rocket!!!

CTIX Stock Message Board http://investorshangout.com/Cellceutix-Corpor...TIX-87375/

I like the volume of the past few weeks. Around 4M total shares traded. This is enough to allow someone (or multiple someone's) to build a decent position. I'm still not sure we have any real institutional buying at this point. The total value of the rally is less than 10M in trade value. (if we were seeing 25-50M in value then I think bigger players are engaging)

I still think this rally is still primarily semi-smart and retail money. Semi-smart are individuals who are professionals with decent portfolios and have a few hundred thousand to play with. They have a higher risk tolerance and play in the margins (looking for high beta stocks) which CTIX may become. However, real "smart money" is going to wait for a drug to be proven to work or if they get wind of a deal or trial outcome. They'll want to deploy 10s of millions into the trade. It's too much work to follow a bunch of small investments.

If the volume and rally continue to build and increase, I'd start to lean towards someone (or a group) taking a decent position (or information is leaking and friends and family are buying in mass).

I'm still planning to add another 100k shares on good news. If Brilacidin works we're on our way to a home run. On it's strength alone $10-20/share is very doable. If we get positive news on Kevetrin and Brilacidin, it could get very exciting.

It should be a fun fall
While TOB has his "Rally [Chimp]," it's time for me to break out my "Rocket to the Moon!" siggie.

Why CTIX?

#1 Brilacidin:

Since the Polymedix acquisition last year, the adding of their assets, and in particular Brilacidin, was not met by an expected increase in valuation. Instead, following the acquisition a long slide from 2.20 region to 1.40 ensued. This in spite of a $200 valuation of the Brilacidin asset prior to Phase 2b trial start. Even as the end of the trial is now official, and the announcement that B-ABSSSI performed at least as expected, the share price is only just now approaching the price just prior to the acquisition a year ago.

Add to the B-ABSSSI Phase 2b announcement that of a pending INDA for Brilacidin-OM, followed by Brilacidin-Ocular, Brilacidin-Otic, and Brilacidin-Diabetic Foot Infections/Ulcers and the Brilacidin value becomes something well north of $200 million. So, discounting and further increased valuation following the Phase 2b trial, the market still does not as of yet recognize any value in the rest of the platform. This will change.

#2 Kevetrin (many would put this at #1)

Kevetrin has long been the flagship drug for CTIX, though arguably recently replaced by Brilacidin. Kevetrin is the platform drug. Following successful Phase 1 studies, there are already 2 more studies planned at world class research centers, MD Anderson and University of Bologna, with a third trial planned at Beth Isreal, all at no, or almost no, cost to CTIX and its shareholders.

Drawbacks to Kevetrin are that it is in the most expensive development arena of biopharma, ontology, and the current trial could go on for at least another 6 months, possibly even a year. Then, there is some question whether or not it will be effective as a stand alone drug, which means to some that developing each combination therapy will mean each requiring a Phase 1b start. CTIX will need funding for these trials, which means partnering, even if a license with $50 million up front is reached for any drug in its pipeline.

On the other hand, as noted above, there is much available in support for a new, effective addition to anticancer therapies, and the efficacy that K targets is considered to be the holy grail of oncology, at least for 50% of all cancers. The high cost and high potential is the balance reflected in the shareprice and cap over the past 18 months, until last week. Nonetheless, the SP is still inside the extended flag reaching all the way back to January 2013.

The question for shareholders, current and future, looking back Brilacidin and the lack of added valuation since its acquisition, to what extent is the current cap reflective of total added values as Brilacidin and its many forms and Kevetrin as an emerging platform? I would postulate that we are currently not more than half way there at $2, and probably a third of the way.

#3 Prurisol

This drug was to be the "meal ticket" for Kevetrin clinical trials until Brilacidin knocked it off its perch. In nonclinical testing, Prurisol was a functional cure of psoriasis. Not just lesion clearance as measured by PASI, but total, full disappearance for the nonclinical trial life of the subject mice. Nonetheless, since Prurisol shifted from proof of concept to FDA trial, several new and effective drugs have won FDA approval. The question remains, with increased competition, will Prurisol prove to be as effective in clinical trials as it has been in nonclinicals? Currently, we would not expect it to add value to the bottom line as the other two drugs now dominate that aspect of CTIX. Still, should Prurisol prove to be what it was in preclinical development, expect a billion dollars in increased cap following such a successful 2/3a trial, a trial that should be short and sweet at about 1 year's duration.

Putting it all together

Should the results of the Brilacidin-ABSSSI trial turn out as many expect--high efficacy, low toxicity, short duration regimen--expect a breakthrough therapy designation with a straight to NDA and clinical approval. In the meantime, clinical trials against other infections as well as formulations are already ramping up. A partnership or license deal should also be in the works and in place in Q1 2015.

Here is the caveat to the partnership and timing, 30 kg of Brilacidin in its current formulation is a lot of product even at the higher dose of 1.8 mg/kg over 3 days. Given Leo's explanation, for future clinical trials, that would be enough product for 250K patients, or 250 trials of 1000 patients each. 250 trials? Really? He expects >200 Phase 2/3 trials over the next year? Sufficient material for 150K patients, enough to treat 25% of all hospitalized ABSSSI for the entire first year, would also have enough left over for another 100 trials of 1000 patients each. Still a lot of trials. Do keep in mind that the other forms of Brilacidin are reformulations, so Leo can't be including those in his future trials.

As for Kevetrin, while a successful Cohort 8 and approval of 9 should be viewed buy the market as a great success, 215 mg/m2 deemed safe, advancement of trials, all trials, are still a year away. Still, each advancing cohort should also add value. And, should Brilacidin result in a partner, those future trials will be fully funded and that will change the valuation metric substantially for the better.

Prurisol will be Prurisol, and once that is clinically proven, it should result in an additional $10 a share over and above any valuation for B and K, if only for its billion dollar market potential.

IMO-FWIW
Interesting to note that CTIX rallied to $2.47 at the end of 2012 with the Kevetrin only at the start of its Phase 1 Clinical Trial at Harvard Cancer Centers.

That was long before Brilacidin made its surprise arrival, with Brilacidin now approaching Phase 2b Clinical Trial results in Q4

That was before the marvelous Aspire financing which allowed CTIX to advance with only minimal dilution. Unusual for an early stage bio-tech.

Now here we are in 2014, at the cusp of a flurry of Clinical Trials for three drugs, Kevetrin, Prurisol and Brilacidin, with Kevetrin now at a very advanced stage and dosage well into the expected therapeutic range with a proven safety profile.

Much justification for a higher CTIX share price, considering Cellceutix is vastly stronger now than it was at the end of 2012.
TOB, we will have to agree to disagree on this point.

But, I'm sure we can agree to agree that things are looking pretty good for CTIX, presently.


INH, Thx for your answer. I agree exciting times ahead for all of us longs. I have been a shareholder since 2011. It feels like it is all coming together now!!!!
Seems so, my friend.

noretreat, your post:

Quote:
a lot of things seem to be coming together nicely right now...


I am especially happy for investors like you, who have taken large and patient positions based on a good understanding of CTIX fundamentals. CTIX is way overdue for some positive recognition.

I think your faith in CTIX will be validated soon.


Excellent summary of events. The only thing I don't agree on is Polymedix management being respected. There were long brewing issues. Many considered the CEO as arrogant and that may have stalled potential partnerships.

For example, take a look at this post on the Polymedix board from Friday, 11/09/12 12:26:08 PM

Scroll down for more posts ▼

Top 10 Most Recent News Articles

PPL's January Dividend Keeps Utility Appeal Intact

Updated Category News Views 50

A dividend notice is rarely thrilling, but it can still separate a steady utility from a story stock peddling fumes. PPL Corporation declared a quarterly common dividend of $0.2850 per share on Nov. 20, payable Jan. 4, 2027. Shareholders must be on the books by Dec. 10, 2026, to receive it. Plain vanilla stuff, yes. Still, plain vanilla is often precisely why utility...

Continue Reading
Label-Free Detection Has a Solid, Narrow Growth Lane

Updated Category News Views 20

Biologics labs are turning into a far better hunting ground for analytical equipment than the old, broad-brush research story suggests. Label-free detection is not a giant market, and nobody should dress it up as one. But the projected move from $0.58 billion in 2026 to $0.85 billion by 2031 points to a useful 8.1% annual growth lane, driven by work researchers genuinely...

Continue Reading
Stowers Brings a Transformation CTO Into Its Lab

Updated Category News Views 125

Data Has Become Lab Infrastructure Microscopes may get the glory, but the plumbing behind modern biology is increasingly digital, sprawling and unforgiving. That is why Stowers Institute for Medical Research appointing Brandon Mayer as vice president and chief technology officer on November 19, 2026, deserves more attention than the usual executive-shuffle treatment. This...

Continue Reading
Intel Investors Face January 12 Lead Plaintiff Deadline

Updated Category News Views 178

A Narrow Calendar Window Has Opened Intel holders have another legal deadline to put on the fridge, and this one is not a casual housekeeping item. A securities class action has been filed in the Northern District of California on behalf of investors who bought or acquired Intel shares between July 23, 2026, and October 29, 2026. The deadline to seek appointment as lead...

Continue Reading
FAA Funding Gridlock Raises Aviation Reliability Risk

Updated Category News Views 95

Friday’s radar and communications trouble delivered the sort of warning nobody in aviation can shrug off: the machinery behind the flight board is getting old, fragile, and far too dependent on people improvising around it. Thousands of flights were delayed or canceled when air traffic control facilities became unstable, according to the Southwest Airlines Pilots...

Continue Reading
Fervo’s 46% Slide Puts Geothermal Claims Under Fire

Updated Category News Views 162

A 46% haircut from an IPO price has a way of stripping the paint off a growth story. Fervo Energy closed at $14.33 after the October 6 report cited in Hagens Berman’s announcement, well below its $27 IPO price from last May. That does not prove the report is right. It does mean NASDAQ:FRVO investors are staring at questions that go straight to the economic spine of...

Continue Reading
Automus and Google Cloud Put Agents to Work on Oracle

Updated Category News Views 68

Oracle back offices are where shiny AI promises go to earn their keep, or get buried under a mountain of integrations. Automus Consulting’s newly announced collaboration with Google Cloud, unveiled November 20 at Oracle AI World, is aimed squarely at that messy middle. The firm wants to combine its Oracle implementation experience with Google Cloud infrastructure and...

Continue Reading
MemorialCare Adds AI Guardrails for Hidden Aneurysms

Updated Category News Views 141

A brain scan ordered for one reason can suddenly expose a risk nobody knew was sitting there. That is the sober promise behind MemorialCare Neuroscience Institute's rollout of Rapid Aneurysm, an artificial-intelligence tool embedded in qualifying CTA and MRA brain scans across its inpatient and outpatient network. MemorialCare says it is the first health system in Los...

Continue Reading
Zesty Takes Kubernetes Cost Control Into GPU Territory

Updated Category News Views 88

GPU waste has become the sort of cloud bill nobody wants to explain upstairs. A company buys scarce, expensive accelerators for AI work, then discovers that real workloads do not politely consume resources in neat, permanent blocks. Demand jumps, memory needs shift, and somebody either over-allocates to avoid trouble or under-allocates and gets ugly out-of-memory...

Continue Reading
Chicago Kertész Show Puts Photography's Quiet Giant First

Updated Category News Views 49

A fork, a plate, and a sharp eye can outlast plenty of louder art. Leica Gallery Chicago is putting that proposition on the wall with André Kertész: The Master, opening December 4, 2026 and running through January 17, 2027. More than thirty signature works is not a sprawling museum survey, and frankly that may be the point. Kertész did not need grand scale to make his...

Continue Reading

Top 5 Most Recently Viewed Articles

BingX Enhances Trading Experience with CScalp Integration

Updated Category News Views 197

BingX Introduces Enhanced Trading Features with CScalp BingX, a prominent name in the cryptocurrency exchange sphere, has recently announced its integration with CScalp, a powerful trading terminal designed for both cryptocurrency and futures traders. This collaboration aims to provide users with cutting-edge trading tools, significantly enhancing their overall trading...

Continue Reading
Moscow Stocks Decline: Insights into Market Performance

Updated Category News Views 106

Moscow Stocks Face a Decline In the latest trading sessions, Moscow stocks have shown a clear downturn, with certain sectors especially driving this trend. The shifting dynamics within these sectors have created a challenging environment for investors. Performance by Sector and Important Takeaways The Telecoms, Mining, and Power sectors have been particularly tough,...

Continue Reading
Innovative Collaboration between Precision for Medicine and PathAI

Updated Category News Views 389

Strategic Alliance for Advancing Clinical Trials In a groundbreaking announcement, Precision for Medicine and PathAI are collaborating to revolutionize clinical trials and biomarker discovery. This partnership is set to introduce the next generation of AI-powered pathology tools designed to enhance quality control in clinical research. Enhancing Clinical Research...

Continue Reading
Declining Brazil Orange Juice Exports: Key Insights & Trends

Updated Category News Views 279

Overview of Brazil's Orange Juice Export Decline Brazil's orange juice exports have faced a significant downturn, with a 19.7% decrease in the first half of the 2024/25 crop season compared to the same time last year, as reported by CitrusBR. This decline represents approximately 535,600 metric tons of juice exports during this period, according to industry data....

Continue Reading
Celebrating 25 Years of Innovation in Legal Marketing

Updated Category News Views 164

Celebrating Two and a Half Decades of Digital Marketing PaperStreet Web Design, a pioneer in legal marketing, proudly marks its 25th anniversary. Founded by attorney and visionary Peter Boyd in 2001, this agency began as a one-person endeavor and has evolved into a nationally recognized firm employing over 30 professionals. With a rich history of aiding more than 2,500...

Continue Reading